State Street
MIRM icon

State Street’s Mirum Pharmaceuticals MIRM Stock Holding History

State Street’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$180M Sell
1,944,281
-199,711
-9% -$18.8M 0.01% 1000
2025
Q4 		$169M Buy
2,143,992
+797,088
+59% +$57.2M 0.01% 1040
2025
Q3 		$98.7M Sell
1,346,904
-28,724
-2% -$1.83M ﹤0.01% 1337
2025
Q2 		$70M Sell
1,375,628
-118,938
-8% -$5.3M ﹤0.01% 1499
2025
Q1 		$67.3M Buy
1,494,566
+112,939
+8% +$5.32M ﹤0.01% 1493
2024
Q4 		$57.1M Sell
1,381,627
-412,101
-23% -$17.2M ﹤0.01% 1649
2024
Q3 		$70M Buy
1,793,728
+297,511
+20% +$11.9M ﹤0.01% 1532
2024
Q2 		$51.2M Sell
1,496,217
-1,326,255
-47% -$34.8M ﹤0.01% 1667
2024
Q1 		$70.9M Buy
2,822,472
+1,087,697
+63% +$29.9M ﹤0.01% 1528
2023
Q4 		$51.2M Buy
1,734,775
+113,865
+7% +$3.45M ﹤0.01% 1695
2023
Q3 		$51.2M Buy
1,620,910
+126,493
+8% +$3.46M ﹤0.01% 1607
2023
Q2 		$38.7M Buy
1,494,417
+323,992
+28% +$8.62M ﹤0.01% 1823
2023
Q1 		$28.1M Sell
1,170,425
-588,193
-33% -$13.4M ﹤0.01% 2000
2022
Q4 		$34.3M Buy
1,758,618
+769,656
+78% +$15.2M ﹤0.01% 1885
2022
Q3 		$20.8M Buy
988,962
+713,095
+258% +$17.2M ﹤0.01% 2193
2022
Q2 		$5.37M Buy
275,867
+143,123
+108% +$3.38M ﹤0.01% 3068
2022
Q1 		$2.92M Buy
132,744
+9,009
+7% +$184K ﹤0.01% 3424
2021
Q4 		$1.97M Sell
123,735
-3,354
-3% -$52.2K ﹤0.01% 3637
2021
Q3 		$2.53M Buy
127,089
+1,303
+1% +$21.2K ﹤0.01% 3549
2021
Q2 		$2.17M Buy
125,786
+35,168
+39% +$630K ﹤0.01% 3533
2021
Q1 		$1.8M Sell
90,618
-4,400
-5% -$84.2K ﹤0.01% 3478
2020
Q4 		$1.66M Sell
95,018
-7,785
-8% -$153K ﹤0.01% 3429
2020
Q3 		$1.98M Buy
102,803
+7,148
+7% +$153K ﹤0.01% 3202
2020
Q2 		$1.86M Buy
95,655
+45,427
+90% +$759K ﹤0.01% 3203
2020
Q1 		$703K Buy
50,228
+27,409
+120% +$450K ﹤0.01% 3377
2019
Q4 		$560K Buy
22,819
+3,203
+16% +$34.1K ﹤0.01% 3504
2019
Q3 		$197K Buy
+19,616
New +$241K ﹤0.01% 3613

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street's MIRM Position: Q1 2026 in Review

State Street reduced its Mirum Pharmaceuticals (MIRM) stake by 9.3% in Q1 2026, selling an estimated $18.8M and leaving 1,944,281 shares worth $180M. The position accounts for 0.01% of the portfolio, ranked #1000.

State Street first reported a position in MIRM in Q3 2019 and has held it in 27 quarters since. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • State Street held 1,944,281 shares of Mirum Pharmaceuticals worth $180M as of Q1 2026.
  • State Street sold 199,711 Mirum Pharmaceuticals shares in Q1 2026, an estimated $18.8M.
  • Mirum Pharmaceuticals made up 0.01% of State Street's portfolio in Q1 2026, its #1000 holding.
  • State Street first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 27 quarters since.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.